Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib

Sequential application of target drugs is standard procedure after renal cell carcinoma (RCC) patients develop resistance. To optimize the sequence, antitumour effects of the mTOR inhibitor RAD001 or the tyrosine kinase inhibitor (TKI) sorafenib on RCC cells with acquired resistance to the TKI sunit...

Descripción completa

Detalles Bibliográficos
Autores principales: Juengel, Eva, Kim, Dana, Makarević, Jasmina, Reiter, Michael, Tsaur, Igor, Bartsch, Georg, Haferkamp, Axel, Blaheta, Roman A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407590/
https://www.ncbi.nlm.nih.gov/pubmed/25444514
http://dx.doi.org/10.1111/jcmm.12471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407590/
https://www.ncbi.nlm.nih.gov/pubmed/25444514
http://dx.doi.org/10.1111/jcmm.12471

Ejemplares similares